This edition of the Drug Discovery TOE depicts the current landscape and the new life sciences trends across the pharmaceutical industry in South Africa. South Africa has a diversified manufacturing industry that focuses on production of pharmaceutical and biotechnology products. Critical programmes were launched by the Department of Trade and Industry (DTI) to promote value adding activities including pharma manufacturing. This study profiles several companies operating at different sites of the value chain. In addition to analyst insights, the corresponding patent scenario is depicted, along with the industry interactions.
The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: South African healthcare market, South African pharmaceutical industry, immunization, vaccines, diphtheria, tetanus, tuberculosis, hepatitis C virus, hepatitis B virus, pertussis, hepatitis B, haemophilus influenzae b, DTP-HepB-Hib, HIV, AIDS, affordable medicines, generics, biosimilars, over the counter drugs